Skip to main content
Wednesday, August 19, 2026
BTC $68,606 ▲ 2.50%
GOKHSHTEIN.
Live WirePoliticsWorldMarketsDigital AssetsTechnologySports
FranchisesThe BriefThe Big ReadThe BreakdownCrypto Culture
More SectionsDeFi & On-ChainU.S. EquitiesMacro & RatesResearch
Subscribe
Menu
NewsLive WirePoliticsWorldMarketsDigital AssetsTechnologySports
FranchisesThe BriefThe Big ReadThe BreakdownCrypto Culture
MoreDeFi & On-ChainU.S. EquitiesMacro & RatesResearch
Subscribe
LIVE
BTC$68,606up+2.50%ETH$2,085up+3.90%SOL$82.31up+6.00%XRP$1.07up+3.50%LINK$9.93up+3.80%ADA$0.182up+1.10%S&P 5007,724up+0.43%Nasdaq26,383up+0.36%Dow53,503up+0.30%RUT3,047up+0.96%TNX4.66%down−1.00%TYX5.21%down−1.51%FVX4.36%down−0.18%IRX3.71%up+0.00%VIX15.18down−4.17%GOLD$4,544.80up+2.81%SILVER$65.68up+2.57%OIL$85.31up+1.49%DXY98.91down−0.75%NVDA$219.38down−0.16%AAPL$316.44up+2.07%TSLA$346.80up+2.95%META$552.17up+1.56%MSFT$486.69up+1.05%AMZN$264.48up+1.94%GOOGL$345.36up+0.34%Fear & Greed46 — FearBTC$68,606up+2.50%ETH$2,085up+3.90%SOL$82.31up+6.00%XRP$1.07up+3.50%LINK$9.93up+3.80%ADA$0.182up+1.10%S&P 5007,724up+0.43%Nasdaq26,383up+0.36%Dow53,503up+0.30%RUT3,047up+0.96%TNX4.66%down−1.00%TYX5.21%down−1.51%FVX4.36%down−0.18%IRX3.71%up+0.00%VIX15.18down−4.17%GOLD$4,544.80up+2.81%SILVER$65.68up+2.57%OIL$85.31up+1.49%DXY98.91down−0.75%NVDA$219.38down−0.16%AAPL$316.44up+2.07%TSLA$346.80up+2.95%META$552.17up+1.56%MSFT$486.69up+1.05%AMZN$264.48up+1.94%GOOGL$345.36up+0.34%Fear & Greed46 — Fear
GOKHSHTEIN.
Media · Est. 2019
The front page of everything. Breaking news and sharp analysis across politics, markets, crypto, technology, and sports — with live market data built in.
Markets
Market OverviewDigital AssetsU.S. EquitiesMacro & RatesResearch
Editorial
Politics & PolicyTechnologySports BusinessResearch
Terminal
GMarketsGo PRO
Company
AboutContactEditorial StandardsCorrectionsAdvertiseSubscribe
Legal
Privacy PolicyTerms of ServiceDisclosures
© 2026 Gokhshtein Media. All rights reserved.
PrivacyTermsDisclosures
Tag

merck

1 article

Merck, Moderna's mRNA Melanoma Vaccine Succeeds in Phase 3 Trial
Research & Analysis1h ago
Merck, Moderna's mRNA Melanoma Vaccine Succeeds in Phase 3 Trial
Intismeran, combined with Keytruda, reduced melanoma recurrence—the first neoantigen vaccine to clear a late-stage randomized trial.